179 related articles for article (PubMed ID: 33002889)
1. Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study.
Kwon W; Jang JY; Song KB; Hwang DW; Kim SC; Heo JS; Choi DW; Hwang HK; Kang CM; Yoon YS; Han HS; Park JS; Hong TH; Cho CK; Ahn KS; Lee H; Lee SE; Jeong CY; Roh YH; Kim HJ;
Neuroendocrinology; 2021; 111(8):794-804. PubMed ID: 33002889
[TBL] [Abstract][Full Text] [Related]
2. Risk Factor Analysis of Lymph Node Metastasis for Rectal Neuroendocrine Tumors: Who Needs a Radical Resection in Rectal Neuroendocrine Tumors Sized 1-2 cm?
Choi JS; Kim MJ; Shin R; Park JW; Heo SC; Jeong SY; Park KJ; Ryoo SB
Ann Surg Oncol; 2024 Apr; 31(4):2414-2424. PubMed ID: 38194045
[TBL] [Abstract][Full Text] [Related]
3. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
4. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
[TBL] [Abstract][Full Text] [Related]
6. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
8. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
[TBL] [Abstract][Full Text] [Related]
9. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study.
Paik WH; Lee HS; Lee KJ; Jang SI; Lee WJ; Hwang JH; Cho CM; Park CH; Han J; Woo SM; Jeong S; Chon HK; Kim TN; Lee JK; Han JH; Yoon JH; Kim YT; Cho JH
Pancreatology; 2021 Jan; 21(1):208-214. PubMed ID: 33281058
[TBL] [Abstract][Full Text] [Related]
10. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
Han S; Kim JH; Yoo J; Jang S
Eur Radiol; 2022 Apr; 32(4):2506-2517. PubMed ID: 34647178
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
[TBL] [Abstract][Full Text] [Related]
12. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).
Jung JG; Lee KT; Woo YS; Lee JK; Lee KH; Jang KT; Rhee JC
Medicine (Baltimore); 2015 Jul; 94(26):e983. PubMed ID: 26131843
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
[TBL] [Abstract][Full Text] [Related]
14. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
16. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
17. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role and predictors of lymph node involvement in pancreatic neuroendocrine tumors.
Ren SJ; Tan QQ; Cao D; Ke NW; Liu XB; Wang X
Eur J Radiol; 2023 May; 162():110772. PubMed ID: 36940547
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
